Talukder, MesbahAfroza, Halima2024-01-092024-01-0920232023-02ID 19146018http://hdl.handle.net/10361/22075Cataloged from PDF version of thesis.Includes bibliographical references (pages 21-25).This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2023.The objective of this study was to investigate the association between TNF-alpha inhibitors and alopecia cases in psoriasis patients reported in the Food and Drug Administration Adverse Event Reporting System (FAERS) database. We performed a disproportionality analysis (case/non-case method) to examine the relationship between the development of alopecia by the use of TNF-alpha inhibitors from January 2016 to September 2022. Cases were all alopecia reports, whereas non-cases were all the other reports reported throughout the research period. We calculated the reported odds ratio (ROR) and corresponding 95% confidence interval (CI) to assess disproportionality signals and determine the relationship between alopecia and TNF-alpha inhibitors. As a positive control, docetaxel was used. Our study found that only infliximab and certolizumab pegol showed signal for alopecia. Additional study into alopecia connected with TNF-alpha inhibitors usage in psoriasis patients is required as disproportionality signals may have been altered by stimulated reporting or nocebo effect.25 pagesenBrac University theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission.PsoriasisAlopeciaTNF-α inhibitorFAERSRORDisproportionality analysisThesis